Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange vs Standard Therapy in Severe Autoimmune Hepatitis
NCT06855667Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Randomised trial (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Number of patients with change in AST, ALT, Bilirubin at 28 days. Planned start Mar 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06855667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855667.